In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Why Early-Stage Dealmaking is Hot

Executive Summary

Big Pharma is in-licensing increasing numbers of preclinical and Phase I compounds despite the fact that their own early-stage productivity is up. Their goal is to increase shots on goal; to pay for the ballooning costs, however, they're increasingly willing to share downstream rights for near-term help on expenses.

You may also be interested in...



The $100 Million IND

An extraordinary series of high-value IND-stage deals could help to solve what has always been the intractable problem for biotechs: how to fund late-stage product development and simultaneously re-fill the early-stage pipeline. Still, it will be the rare biotech that can pull off this strategy--which requires INDs in the hottest areas of pharmaceutical development.

Trade Sales Trump IPOs, Even for Platforms

Europe's summertime flurry of private biotech sell-offs points to growing pragmatism among management and VCs, and still-poor valuations on the public markets. Firms which haven't already considered the trade sale opportunity should do so--even early-stage, pre-product platform groups.

Curis Reformed: Unearthing Preclinical Value

From its start as a promising powerhouse in the emerging area of regenerative medicine and through product failures, valuation crunches and capital constraints, Curis has in the past two years embraced an almost old-school approach to the biotechnology business. Bereft now of the late-stage assets (and corresponding cash burn) that helped drive its formation through merger in 2000, the company has leveraged its preclinical expertise in cell signaling to sign broad, value-creating alliances with top-shelf biotechnology and pharmaceutical partners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel